



## **PUBLICATIONS**

30 March 2022

## **MAPS**

FY 2021 (=)

(Company press release)

## In Line with Projections

The company has released 2021 results that landed in line with our estimates. Revenue amounted to €21.5m (vs. €22.1m estimated), up by more than 20%. Notably, the Healthcare and ESG divisions recorded an increase of 62% and 69% vs. 2020. The proportion of recurring revenue continues to grow (+49%) and now accounts for almost 35% of revenue vs. 28% in 2020.

EBITDA stands at €5.0m (vs. €6.2m estimated), representing a 48% increase. Thus, the 4.4 point margin increase to 23.4% is due to the larger share of recurring revenue and proprietary software sales (72% of revenue vs. 53% in 2020).

The group recorded a net result of €2.5m, up 145% vs. 2020. Net debt improved to €4.9m vs. €7.0m at end-2020.

This solid publication supports our outlook, which therefore remains unchanged. We are reiterating our TP of €5.8 as well as our Buy rating.

Buy, TP of €5.8 - Alessandro Cuglietta: +33178957164

Market Data		
Industry	Software	
Share Price (€)	3.5	
Market Cap (€M)	39.6	
Market Segment	Euronext Growth Milan	
Bloomberg	MAPS IM	

8%
2%
1%

€M (31/12)	2021	2022	2023	2024
VoP (€M)	23.5	29.9	33.5	36.8
Growth	15.9%	27.2%	12.0%	9.8%
<b>EBITDA</b>	5.0	8.1	9.3	10.5
Marge EBITDA	21.4%	27.1%	27.9%	28.4%
Net income	2.5	3.4	3.7	4.0
EPS €	0.20	0.27	0.30	0.32
Growth	106.7%	33.3%	10.9%	7.9%
Dividende par act	0.00	0.00	0.00	0.00
Yield (%)	0.0%	0.0%	0.0%	0.0%
FCFF	-3.2	0.5	2.9	4.0
ROCE	10.4%	11.1%	11.9%	12.7%
EV/EBITDA (x)		5.9	5.1	4.6
EV/EBIT (x)		9.9	9.0	8.3
PE (x)		10.8	9.7	9.0
Net Debt	4.9	4.5	1.8	-2.0
Gearing, net	13%	12%	5%	-6%

TP ICAP Midcap estimates

Upcoming event : 23 September - H1 2022